Hormones
1-minute read
Follow the links below to find trusted information about hormones.
Last reviewed: May 2018
Need more information?
These trusted information partners have more on this topic.
Top results
Pituitary hormones initiatives
This page contains information on the relation between human pituitary hormone treatment and Creutzfeldt-Jakob disease (CJD) as well as Government's initiatives for the control and prevention of CJD.
Read more on Department of Health website
Thyroid gland and thyroid hormones - myDr.com.au
The thyroid gland produces thyroid hormones - the main ones being T3 (triiodothyronine) and T4 (thyroxine).
Read more on myDr website
Hormone replacement therapy - myDr.com.au
Hormone replacement therapy (HRT) is not a quick fix to the challenge of menopause, but it can be a useful tool in the overall management of menopause.
Read more on myDr website
Bioidentical Hormones for Menopausal Symptoms - Australasian Menopause Society
Many women want to deal with menopausal symptoms `naturally` and may turn away from prescribed traditional hormone therapy (`HRT`) in favour of so-called `bioidentical` hormone treatments.
Read more on Australasian Menopause Society website
What is Menopausal Hormone Therapy (HRT)? - Australasian Menopause Society
Professor Susan Davis discusses the basics of menopausal hormone therapy (HRT).
Read more on Australasian Menopause Society website
Is Menopausal Hormone Therapy (HRT) safe? - Australasian Menopause Society
Professor Rod Baber discusses the safety of menopausal hormone therapy (HRT).
Read more on Australasian Menopause Society website
Climara | myVMC
Climara is a form of hormone replacement therapy used in menopause. It delivers a synthetic form of oestrogen, oestradiol, via a skin patch.
Read more on myVMC – Virtual Medical Centre website
Estrofem | myVMC
Femoston is a combination hormone replacement therapy containing dydrogesterone (progesterone) and oestradiol (oestrogen) used to treat menopausal symptoms.
Read more on myVMC – Virtual Medical Centre website
Pituitary tumour
Generally, pituitary tumours are benign (not cancerous) and slow growing, and pituitary cancers are rare. Benign tumours don’t spread to other parts of the body, so there is no chance of secondary tumours developing. Treatment may include surgery, radiation therapy and medication.
Read more on Better Health Channel website
Thyroid gland disorders - myDr.com.au
The average person knows little about the detrimental affects of thyroid disorders upon health and this can be very discouraging.
Read more on myDr website
Top results
Gonadotrophin-releasing hormone antagonists versus GnRH agonist in subfertile couples undergoing assisted reproductive technology | Cochrane
Gonadotrophin-releasing hormone antagonists versus GnRH agonist in subfertile couples undergoing assisted reproductive technology
Read more on Cochrane (Australasian Centre) website
Gonadotrophin-releasing hormone antagonists in subfertile couples undergoing ovulation induction as part of an assisted conception program | Cochrane
Read more on Cochrane (Australasian Centre) website
Growth hormone in in-vitro fertilisation | Cochrane
Before starting an in-vitro fertilisation cycle, some women need help to ovulate and the use of growth hormone therapy may help these women. This aims to reduce the use of gonadotropin therapy to stimulate ovulation, a hormone that can cause multiple pregnancy. The review of trials found no evidence that growth hormone helps improve birth rates in women who are undergoing ovulation induction prior to in-vitro fertilisation. However there is some evidence of increased pregnancy and birth rates in women who are considered 'poor responders' to in-vitro fertilisation. More research is needed.
Read more on Cochrane (Australasian Centre) website
Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia | Cochrane
A systematic overview of randomised trials does not provide sufficient evidence to determine whether thyroid hormone treatment of preterm infants with transiently low thyroid hormone levels results in changes in neonatal outcomes or reductions in developmental impairments. Extremely premature infants frequently have transiently low thyroid hormone levels in the first weeks after birth. These low thyroid hormone levels are associated with an increased incidence of complications and death in the newborn period and longer term developmental impairments. Thyroid hormone therapy might prevent these problems. One small trial comparing thyroid hormone treatment to no treatment of infants with transiently low thyroid hormone levels reported no benefit from treatment of these infants. However, this is insufficient evidence to determine if thyroid hormone treatment is effective. Further research is needed.
Read more on Cochrane (Australasian Centre) website
Thyroid hormones for preventing neurodevelopmental impairment in preterm infants | Cochrane
No evidence from trials that thyroid hormone therapy is effective in preventing problems such as respiratory distress syndrome in preterm babies. Thyroid hormones are needed for the normal growth and maturity of the central nervous system, as well as the heart and lungs. Children born without sufficient thyroid hormones can develop serious mental retardation. It is believed that low levels of thyroid hormones in the first few weeks of life (transient hypothyroxinemia) in preterm babies born before 34 weeks may cause this abnormal development. The review of trials found no evidence that using thyroid hormones in preterm babies is effective in reducing the risk of problems caused by insufficient thyroid hormones.
Read more on Cochrane (Australasian Centre) website
Growth Hormone Deficiency Childhood | Australian Sports Anti-doping Authority - ASADA
Growth Hormone deficiency refers to a disorder of the hypothalamus or pituitary gland in which Growth Hormone production is impaired. Treatment of Growth Hormone deficiency is by supplementation with Growth Hormone, which is prohibited at all times in sport.What information is required for a Therapeutic Use Exemption (TUE) application?ASDMAC will not consider granting a TUE without the following information:
Read more on Australian Sports Anti-Doping Authority (ASADA) website
Recombinant growth hormone for idiopathic short stature in children and adolescents | Cochrane
There is some evidence that recombinant human growth hormone improves short term growth and (near) final adult height in children with idiopathic short stature.
Read more on Cochrane (Australasian Centre) website
Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants | Cochrane
A systematic review of the data from randomised controlled trials provides no evidence that routine thyroid hormone therapy is effective in preventing problems in preterm babies or improves their developmental outcomes. Thyroid hormones are needed for the normal growth and maturity of the central nervous system, as well as the heart and lungs. Children born without sufficient thyroid hormones can develop serious mental retardation. It is believed that low levels of thyroid hormones in the first few weeks after birth (transient hyperthyroxinaemia) in preterm babies born before 34 weeks may contribute to this abnormal development. The review of trials found no evidence that using thyroid hormones routinely in preterm babies is effective in reducing the risk of problems caused by transiently low levels of thyroid hormones.
Read more on Cochrane (Australasian Centre) website
Human growth hormone for treating burns and skin graft donor sites | Cochrane
Growth hormone is produced by the pituitary gland. For decades, it could only be obtained by extraction from pituitary glands but more recently it has been produced through genetic engineering and made available for therapy as recombinant human growth hormone (rhGH). The aim of this review was to determine the effects of rhGH when used to treat burns and skin graft donor sites and to determine its safety compared with other treatments.
Read more on Cochrane (Australasian Centre) website
Adjuvant gonadotropin-releasing hormone analogues for chemotherapy induced premature ovarian failure in premenopausal women | Cochrane
Adjuvant gonadotropin-releasing hormone analogues for chemotherapy induced premature ovarian failure in premenopausal women
Read more on Cochrane (Australasian Centre) website
